Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD
Novel subcutaneous delivery may offer a more patient-friendly…Read More
You might also be interested in reading Report: Paradigm Raises $1.2 Billion as AI Funding Outpaces Crypto Deals in 2026.